FDA Approves XGEVA For Prevention Of Events In Patients With Bone Metastases From Solid Tumors
Amsterdam Molecular Therapeutics BV Amends GDNF Gene License Agreement
Announces Top Line Results From Phase 3 Trial Evaluating XGEVA
Sees FY 2010 EPS Guidance At Above Middle Of Prior
Issues FY 2011 EPS Guidance Below Estimates
And Amgen Inc Initiate Phase IIb Clinical Trial Of Intravenous Formulation Of Omecamtiv Mecarbil
Completes Acquisition of BioVex
The Takeda Oncology Company And Takeda Pharmaceutical Company Limited Announce Results From Pivotal Phase 3 Motesanib Trial
Buys Brazilian Company For
Reaffirms FY 2015 Call
Receives Positive Opinion From Committee For Medicinal Products For Human Use For XGEVA In European Union
AstraZeneca PLC To New Drug Denosumab With DAIICHI SANKYO
Announces New Results From Multiple Studies Of ENBREL
Hypermarcas SA Announces Sale of Distribuidora de Produtos Farmaceuticos Ltda to Amgen Brasil Biofarmaceutica Ltda
FDA Aims For April Decision On Xgeva For Prostate
Issues FY 2015 Guidance In Line With Call
Announces FDA Approval For New Indications for Prolia For Treatment Of Bone Loss
To Lay Off 380
Raises FY 2011 Guidance
To Supply Epogen To DaVita In New
Presents Final Results From Phase 3 Study Assessing Safety And Efficacy Of Nplate
And Watson Announces Collaboration To Develop And Commercialize Oncology Biosimilars
Comments On FY 2012 Call
Completes Tender Offer For Outstanding Shares Of
and AstraZeneca PLC Announce Collaboration To Jointly Develop And Commercialize Inflammation Portfolio
UCB SA and Initiate Sclerostin Antibody Phase 3 Program in Patients with Postmenopausal Osteoporosis
Announces Second Quarter Dividend
Announces 2012 Third Quarter Dividend
Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
Amgen Inc Reaffirms FY 2012 Call
Amgen Inc Announces 2012 Fourth Quarter Dividend
Amgen Inc Issues FY 2012 Guidance Above Estimates
Slumps On
